AstraZeneca (AZN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sachin Jain from Bank ...

By Bhanvi Satija (Reuters) -Johnson & Johnson said on Tuesday its chemotherapy-free combination treatment showed a meaningful ...

SAN DIEGO, CA / ACCESSWIRE / January 9, 2025 / Robbins LLP reminds investors that a class action was filed on behalf of all ...

AstraZeneca AZN stock has declined 14% in the past three months. A lot of this price decline is due to ongoing investigations ...

Shares of AstraZeneca PLC AZN inched up 0.81% to £107.54 Wednesday, on what proved to be an all-around positive trading ...

Johnson & Johnson says its bispecific antibody, paired with a Janssen drug, could change treatment for non-small lung cancer ...

Johnson & Johnson’s combination of Rybrevant and Lazcluze has racked up an overall survival (OS) victory against ...

As we enter 2025, many growth stocks are trading at high valuations and could be running out of room to rise in the near term ...

The ADR's fall snapped a three-day winning streak.

Johnson & Johnson said a combination of its lung cancer drugs Rybrevant and Lazcluze kept people alive for at least a year ...

A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung ...

AstraZeneca has been taking a wider role in Vietnam’s healthcare sector to help expand access to quality healthcare.